We value your privacy

We use cookies to enhance your browsing experience, serve personalized content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Cookie Policy. By using this site you agree to our Terms and Conditions.

ortex-logo-h
​
​
LSE:0LIF
​
​
logo

Ultragenyx Pharmaceutical Inc. (0LIF)

LSE • 0LIF • US90400D1081

17.50Last close
Market Closed
Overview
Fundamentals
Events
News
Corp Actions
Index
Analysts
EPS Momentum
Holders
Dividend
Shorts
Insiders
Peers
Commodity Exp
Trading Signals
Stock Scores

ORTEX Data Highlights

As of Nov 3, 2026, ORTEX estimates 3.4% of free float is sold short, 366.5 days to cover, cost to borrow 0.42%.

Market Cap

1.69b USD | # 1891 in GB

Volume

19.99k shares | 81.26m USD

Shares Outstanding

98.29m

Free Float Shares

75.39% | 74.1m

Nasdaq:RARE|
DB:UP0|
XTRA:UP0|
BOVESPA:R2AR34

News

0LIF key data

Ultragenyx Pharmaceutical Inc. (LSE: 0LIF) has a market capitalization of $1.69B. Last close $17.50 (as of 2026-11-05); 52-week range $12.87 to $41.50. ORTEX data as of 2026-11-03: short interest is 3.38% of free float, 366.5 days to cover and the average cost to borrow is 0.42%.

  • 0LIF news on ORTEX News
  • ORTEX News
  • ORTEX public data
  • ORTEX Charts
  • ORTEX API

© 2026 ORTEX Technologies Ltd.